Britain earmarks £50 million for NHS genetics

'Genetics offers prediction of risk, more precise diagnosis, more targeted and effective use of existing drugs, new gene-based drugs and therapies, and prevention and treatment regimes tailored to an individual's genetic profile.'

Photo: Britain earmarks £50 million for NHS genetics

A ‘Genetics Strategy for the NHS - ‘Our Inheritance, Our Future - Realising the Potential of Genetics in the NHS’, presented to Parliament in late June by John Reid, Secretary of State for Health, aims to set out a vision of how patients could benefit from future advances in genetics, and raise awareness of the potential of genetics in healthcare.

The ‘White Paper’ sets out a comprehensive plan to prepare the NHS, and includes an investment of £50 million over the next three years towards this initiative, by 
 Substantially upgrading genetics laboratories, and boosting the genetics workforce: more genetics counsellors, consultants and laboratory scientists
 Spending over £7 million on new initiatives to introduce genetics-based healthcare into the mainstream of the National Health Service
 Setting up a new Genetics Education and Development Centre to spearhead education and training in genetics for all healthcare staff
 Funding a new research programmes in pharmacogenetics, gene therapy and health services research to help turn the science into real patient benefit.

Safeguards and controls against inappropriate or unsafe use of genetics developments are also set out. In addition to existing controls on gene therapy and use of genetic test results by insurers, new legislation is planned, to ban DNA theft: it will become an offence to test someone’s DNA without their consent except for medical or police purposes.

The Government said it recognises the importance of openness and public debate, and will continue to respond to new developments and shifts in public attitudes

01.07.2003

More on the subject:

Related articles

Photo

Article • Hengrui Pharma charts its global strategy at ESMO

Meet the Chinese company advancing European oncology

Hengrui, one of China's leading pharmaceutical companies, is preparing to bring its cancer therapies to international markets. At the ESMO congress in Berlin, Yuting (Shelley) Liu, Head of China…

Photo

News • Weight loss and diabetes medication

GLP-1 agonists may interfere with cancer imaging, new study finds

GLP-1 receptor agonists are widely prescribed for individuals with diabetes and weight loss. However, these medications may adversely affect the interpretation of cancer imaging, new research finds.

Photo

Article • Opioid and alcohol-related disorders in healthcare

Managing inpatients with substance abuse disorders

The number of patients with substance abuse disorders who are admitted to hospitals as inpatients has been steadily increasing. Hospitalists attending SHM Converge 2025, the annual meeting of the…

Subscribe to Newsletter